KLK3 and prostate carcinoma: Preliminary data from a Phase I/II trial of liposomal BNT112 encoding the five prostate cancer-specific antigens, kallikrein-2, kallikrein-3, acid phosphatase prostate, HOXB13, and NK3 homeobox 1, as monotherapy or in combination with cemiplimab, in metastatic castration resistant prostate cancer (mCRPC) showed that all five antigens were immunogenic and responses to each antigen were observed in at least two patients [198].